Background Guideline-recommended dual antiplatelet therapy (DAPT; aspirin plus
prasugrel/ticagrelor) for 12 months in acute coronary syndrome (ACS) patients increases …

Background To study the impact of de-escalation antiplatelet therapy retaining P2Y12
inhibition on major bleeding and ischemic outcomes after percutaneous coronary …

Objective To estimate the incidence and HRs for bleeding for different dual antiplatelet
therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) …

Objectives The aim of this study was to compare short dual antiplatelet therapy (DAPT) and
de-escalation in a network meta-analysis using standard DAPT as common comparator …

Background Despite guideline recommendation of dual antiplatelet therapy (DAPT) in
treating ACS, DAPT is underutilized. Our objective was to determine independent predictors …

(PCI), a 6-to 12-month course of dual antiplatelet therapy (DAPT) with aspirin and a P2Y12
receptor inhibitor is typically prescribed to mitigate the risk of thrombotic complications at the …

The assessment of bleeding and ischemic risk is a crucial step in establishing appropriate
composition and duration of dual antiplatelet therapy (DAPT) in patients with acute coronary …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Background: Antiplatelet therapy deescalation has been suggested as an alternative to
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …

Dual antiplatelet therapy (DAPT) is the gold standard for the antithrombotic management of
patients with an acute coronary syndrome (ACS) or undergoing percutaneous coronary …